VELCADE(R) For Injection Based Therapies Show Consistently High Complete And Near Complete Response Rates In Front-Line Multiple Myeloma Trials

... Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today reported the presentation of results of several clinical trials of VELCADE(R) (bortezomib) for Injection in combination with a variety of agents, including DOXIL(R) (pegylated liposomol doxorubicin) and dexamethasone, for the treatment of newly diagnosed multiple myeloma (MM) patients. [click link for full article] ...